Ona Therapeutics, a Spain-based global biopharmaceutical company pioneering first-in-class ADCs to address treatment-resistant cancers, has closed an oversubscribed US$86.6m Series B financing. The round was co-led by new investors Columbus…
Spain: Ona Therapeutics raises US$86.6m Series B to advance First-in-Class ADCs into clinical development
…
…






